Majid Shahbaz, MD
Geriatric Medicine · la Mesa, CANPI 1790966018
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 538 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations. Among geriatric medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 538 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$1K
- Amgen$1K
- AbbVie$951
- Boehringer Ingelheim$586
- Amarin Pharma, Inc.$571
- plus $5K from 47 others
What the payments were for
- Food & beverage$10,52599%
- Education$1531%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$630
- AIRSUPRA$393
- Barostim Neo System$267
- BREZTRI$240
- OFIRMEV$121
- Kerendia$119
- BREZTRI AEROSPHERE$112
- LifeVest$100
How this compares
$10,679 in reported general payments places this provider in the 95th percentile of 494 geriatric medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 360 | $440,838 |
| JardianceEmpagliflozin | 328 | $420,606 |
| EliquisApixaban | 248 | $286,425 |
| FarxigaDapagliflozin Propanediol | 253 | $277,565 |
| TrulicityDulaglutide | 116 | $159,768 |
| ProliaDenosumab | 76 | $133,086 |
| EntrestoSacubitril/Valsartan | 117 | $131,448 |
| XareltoRivaroxaban | 98 | $99,941 |
| LinzessLinaclotide | 121 | $85,367 |
| GemtesaVibegron | 54 | $53,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $41,968 |
| Repatha SureclickEvolocumab | 52 | $37,764 |
| Diclofenac Sodium | 101 | $34,030 |
| MounjaroTirzepatide | 25 | $31,948 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 19 | $27,663 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Stiolto Respimat, Spiriva Respimat | $586 | $484,958388 claims |
| Novo NordiskOzempic, Rybelsus | $1,336 | $468,212387 claims |
| AstraZenecaFarxiga, Brilinta | $1,253 | $298,041280 claims |
| PfizerEliquis | $570 | $286,425248 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $477 | $191,717141 claims |
| AmgenProlia | $1,216 | $133,08676 claims |
| NovartisEntresto | $336 | $131,448117 claims |
| Johnson & JohnsonXarelto | $139 | $99,94198 claims |
| AbbVieLinzess | $951 | $85,367121 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $70 | $82,834118 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $155 | $53,89054 claims |
| Astellas Pharma US IncMyrbetriq | $296 | $19,50017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 494 geriatric medicine providers in California.
Other geriatric medicine in la Mesa
- Robert FeldmanLaguna Hills$1.2M
- Oscar ChienSan Gabriel$208K
- Anders NybergSan Diego$160K
- Paul AisenSan Diego$70K
- Wayne ChenLos Angeles$40K
- Vincent HoLancaster$32K
- Kathryn SewellSan Francisco$26K
- Stephen HenryPasadena$25K
- Chaewon SongGarden Grove$21K
- Douglas ZhangSan Leandro$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.